Can-Fite BioPharma (CANF) shareholders approve five proposals at 2026 AGM

Rhea-AI Filing Summary

Can-Fite BioPharma Ltd., an Israel-based foreign private issuer, reports that its Annual General Meeting of Shareholders held on June 4, 2026 approved all five proposals presented to shareholders. These proposals were previously detailed in the company’s Notice and Proxy Statement dated April 23, 2026, which had been furnished to the SEC on Form 6-K.

Key Figures

Number of proposals approved: 5 proposals AGM date: June 4, 2026 Proxy statement date: April 23, 2026

3 metrics

Number of proposals approved 5 proposals Annual General Meeting of Shareholders on June 4, 2026

AGM date June 4, 2026 Annual General Meeting of Shareholders approval of proposals

Proxy statement date April 23, 2026 Notice and Proxy Statement describing the five proposals

Key Terms

Annual General Meeting of Shareholders, Proxy Statement, Form 6-K, foreign private issuer

4 terms

Annual General Meeting of Shareholders financial

"On June 4, 2026, the Annual General Meeting of Shareholders of Can-Fite BioPharma Ltd."

Proxy Statement financial

"Each of those proposals was described in the Company’s Notice and Proxy Statement"

A proxy statement is a document companies send to shareholders ahead of a meeting that lays out the items up for a vote—like who will sit on the board, executive pay, and major corporate decisions—and provides background so shareholders can decide how to cast their votes or appoint someone to vote for them. Think of it as an agenda plus a ballot and briefing notes, important because the outcomes can change control, strategy, and value.

Form 6-K regulatory

"attached as Exhibit 99.1 to the Company’s Form 6-K that was furnished"

A Form 6-K is a report that companies listed in certain countries file to provide important updates, such as financial results, corporate changes, or other significant information, to regulators and investors. It functions like an official company update or news release, helping investors stay informed about developments that could affect their investment decisions.

foreign private issuer regulatory

"FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16"

A foreign private issuer is a company organized outside the United States that meets tests showing it is primarily foreign-controlled and therefore qualifies for a different set of U.S. reporting rules. For investors, that means the company files less frequent or differently formatted disclosures with U.S. regulators and may follow home-country accounting and governance practices, so buying its stock is like dining at a well-reviewed restaurant that follows its home kitchen’s rules instead of the local menu — you get access but should check what standards apply.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

For the Month of June 2026

001-36203

(Commission File Number)

CAN-FITE BIOPHARMA LTD.

(Exact name of Registrant as specified in its charter)

26 Ben Gurion Street

Ramat Gan 5257346 Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

On June 4, 2026, the Annual General Meeting of Shareholders of Can-Fite BioPharma Ltd. (the “Company”) approved each of the five proposals brought before the Company’s shareholders at the meeting, in accordance with the majority required for each proposal. Each of those proposals was described in the Company’s Notice and Proxy Statement with respect to the Company’s Annual General Meeting of Shareholders, dated April 23, 2026, attached as Exhibit 99.1 to the Company’s Form 6-K that was furnished to the U.S. Securities and Exchange Commission on April 23, 2026.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Date: June 4, 2026	By:	/s/ Motti Farbstein
		Motti Farbstein
		Chief Executive Officer and Chief Financial Officer

2

FAQ

What did Can-Fite BioPharma Ltd. (CANF) announce in this Form 6-K?

Can-Fite BioPharma reported that shareholders approved all five proposals at its June 4, 2026 Annual General Meeting. The proposals were previously described in a Notice and Proxy Statement dated April 23, 2026.

How many proposals did CANF shareholders approve at the June 2026 meeting?

Shareholders approved five proposals at the June 4, 2026 Annual General Meeting. Each proposal received the required majority, as outlined in the company’s April 23, 2026 Notice and Proxy Statement filed on Form 6-K.

When was Can-Fite BioPharma’s 2026 Annual General Meeting of Shareholders held?

The Annual General Meeting of Shareholders was held on June 4, 2026. At this meeting, Can-Fite BioPharma’s shareholders approved all five proposals that had been described in the April 23, 2026 proxy materials.

Where can investors find details of the proposals approved by CANF shareholders?

Details of the five approved proposals are in Can-Fite BioPharma’s Notice and Proxy Statement dated April 23, 2026. That document was attached as Exhibit 99.1 to a Form 6-K furnished to the SEC on the same date.

What type of SEC report did Can-Fite BioPharma (CANF) file for this update?

Can-Fite BioPharma filed a Form 6-K, which is used by foreign private issuers to report material information. This specific Form 6-K discloses the voting results from the June 4, 2026 Annual General Meeting.

Who signed the June 4, 2026 Form 6-K for Can-Fite BioPharma Ltd.?

The Form 6-K was signed by Motti Farbstein, who serves as Chief Executive Officer and Chief Financial Officer. The signature is dated June 4, 2026, consistent with the date of the Annual General Meeting.